ArticleCancer discovery2018
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03620643 (Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours), which is not on this map. Cited by 80 papers.
0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
Who cites it
80 citing papers in PubMed, 129 citations in OpenAlex.
- PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.Nature cancer · 2023Trial
- Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.Breast cancer research and treatment · 2022Trial
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer.JCI insight · 2026Article
- Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells.iScience · 2026Article
- Restoration of E-cadherin Expression Alters Metastatic Organotropism in Invasive Lobular Breast Carcinoma Models.bioRxiv : the preprint server for biology · 2026Article
- LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.Cancer research · 2026Article
- Clustering and a conformational switch drive activation of the mammalian receptor tyrosine kinase ROS1.Nature communications · 2026Article
- A multimodal framework to identify molecular mechanisms driving patient group-associated morphology through the integration of spatial transcriptomics and whole slide imaging.NPJ artificial intelligence · 2026Article
- Synthetic lethality in cancer drug discovery: challenges and opportunities.Nature reviews. Drug discovery · 2026Review
- Molecular and Biological Features of Invasive Lobular Carcinoma: Toward New Treatment Strategies.Annals of surgical oncology · 2026Review
- Normal bronchial field basal cells show persistent methylome-wide impact of tobacco smoking, including in known cancer genes.Epigenetics · 2025Article
- ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection.Histopathology · 2025Article
- Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review).International journal of oncology · 2025Review
- Review
- Review
- Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.NPJ breast cancer · 2025Review
- Comprehensive characterization of invasive mammary carcinoma with lobular features: integrating morphology and E-cadherin immunohistochemistry patterns.Breast cancer (Tokyo, Japan) · 2025Article
- Molecular Basis of Breast Tumor Heterogeneity.Advances in experimental medicine and biology · 2025Review
- E-Cadherin-Mediated Cell-Cell Adhesion and Invasive Lobular Breast Cancer.Advances in experimental medicine and biology · 2025Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 7 institutions in 5 countries.
Ilirjana BajramiThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Rebecca MarlowThe Breast Cancer Now Research Unit, King's College London, London, United Kingdom.
Marieke van de VenMouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rachel BroughThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Helen N PembertonThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Jessica FrankumThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Feifei SongThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Rumana RafiqThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Asha KondeThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Dragomir B KrastevThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Malini MenonThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
James CampbellThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Aditi GulatiThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Rahul KumarThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Stephen J PettittThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Mark D GurdenThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Marta Llorca CardenosaThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Irene ChongThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Patrycja GazinskaThe Breast Cancer Now Research Unit, King's College London, London, United Kingdom.
Fredrik WallbergFACS Core Facility, The Institute of Cancer Research, London, United Kingdom.
Elinor J SawyerDivision of Cancer Studies, Guy's Hospital, King's College London, London, United Kingdom.
Lesley-Ann MartinThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Mitch DowsettThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Spiros LinardopoulosThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Rachael NatrajanThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Colm J RyanSystems Biology Ireland, University College Dublin, Dublin, Ireland.
Patrick W B DerksenDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jos JonkersDivision of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Andrew N J TuttThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Alan AshworthUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. Chris.Lord@icr.ac.uk alan.ashworth@ucsf.edu.
Christopher J LordThe Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. Chris.Lord@icr.ac.uk alan.ashworth@ucsf.edu.
Breast Cancer Now · GBCancer Genomics Centre · NLInstitute of Cancer Research · GBKing's College London · GBUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity College Dublin · IEUtrecht University · NL
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7MCancer Research UK 11566Cancer Research UK 14276Cancer Research UK 22897Cancer Research UK 24439Cancer Research UK C30061/A24439Medical Research Council MC_PC_14105NCI NIH HHS P30 CA082103Wellcome TrustWellcome Trust 103049/Z/13/Z
Abstract
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered
Indexed as
AnilidesAnimalsAntigens, CDAntineoplastic AgentsBreast NeoplasmsCadherinsCell Line, TumorCrizotinibFemaleHumansMiceMutationProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsQuinolinesAnilidesAntigens, CDAntineoplastic AgentsCadherinsCDH1 protein, humanCrizotinibGSK 1363089Protein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsQuinolinesROS1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03620643ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.